NEW YORK (GenomeWeb) – New research has helped illuminate how physicians are using Genomic Health's Oncotype DX to guide treatment decision-making for women with early-stage breast cancer: whether they tend to order the test in the correct circumstances, and how they then act on the results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.